TTrialPathMatch Me to Trials
← Back to trials
RecruitingOpen Angle Glaucoma

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.

Sponsor: Prairie Eye Center

You may qualify if…

  • ✓ Adults aged Eighteen (18) years and older with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month. Evidence of optic nerve damage will be based on AAO Preferred Practice Patterns guidelines using either or both of the following:
  • ✓ Optic disc or retinal nerve fiber layer (RNFL) structural abnormalities
  • ✓ Diffuse or focal narrowing, or notching, of the optic disc rim, especially at the inferior or superior poles, which forms the basis for the ISNT rule
  • ✓ Progressive narrowing of the neuroretinal rim with an associated increase in cupping of the optic disc
  • ✓ Diffuse or localized abnormalities of the parapapillary RNFL, especially at the inferior or superior poles
  • ✓ Disc rim, parapapillary RNFL, or lamina cribrosa hemorrhages
  • ✓ Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue
  • ✓ Large extent of parapapillary atrophy

You may not qualify if…

  • ✕ Patients with prior ocular procedures or intraocular surgery within 1 year prior to baseline (e.g. cataract surgery).
  • ✕ Patients with prior history of glaucoma surgeries or laser treatment except patients with history of SLT \>1 yr prior to baseline.
  • ✕ Contraindications or known hypersensitivity to any or all the study medications including Rocklatan, Simbrinza, Cosopt and Latanoprost or related class of drugs.
  • ✕ Patients with known history or presence of uncontrolled systemic diseases including diseases that, in investigator's opinion, may make it unsafe or undesirable for the subject to participate in the study and/ or limit adherence.
  • ✕ Patients with known history or presence of significant ocular diseases including corneal diseases, dystrophies or abnormalities that would prevent accurate IOP readings with GAT.
  • ✕ Patients with a history of uncontrolled IOP with the combination of either Rocklatan + Simbrinza or Cosopt + Latanoprost dual therapy.
  • ✕ Significant ocular surface findings (e.g. hyperemia, irritation) found during slit lamp examination that might affect the study.
  • ✕ Chronic use of any systemic medication for chronic diseases that may affect IOP.

Where it's recruiting

Illinois

Springfield

Source: ClinicalTrials.gov · NCT06883123 · last updated 2025-05-15

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost · TrialPath